The pressure and uncertainty of 2023 will likely continue for drug manufacturers in 2024, with the election cycle bringing added scrutiny. At the federal level, continuing implementation of the Inflation Reduction Act, including publication of the so-called negotiated prices, may be disruptive. The states, meanwhile, will likely move forward with their own drug pricing initiatives, including statutes seeking to regulate the federal 340B program. Manufacturers have responded with greater willingness to challenge overreach in court, a trend that is likely to continue in 2024. In this episode of Connected with Latham, Washington, D.C. partner Chris Schott and associate Danny Machado examine some of the challenges that lie ahead for drug manufacturers.
Also refer to a recent Bloomberg Law article authored by Chris on the same topic.
This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York’s Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York’s Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Episode 78 – UK FinReg Focus Areas in 2024: ESG
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
HCI Leadership Revolution
Human Capital Leadership
The Power of Music Thinking
BusinessWISE
Business Wars